MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

BioNTech SE ADR

Slēgts

SektorsVeselības aprūpe

93.19 3.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

88.38

Max

94

Galvenie mērījumi

By Trading Economics

Ienākumi

143M

301M

Pārdošana

-55M

1.2B

EPS

1.08

Peļņas marža

25.311

Darbinieki

6,772

EBITDA

253M

464M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+54.57% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3.3B

23B

Iepriekšējā atvēršanas cena

89.69

Iepriekšējā slēgšanas cena

93.19

Ziņu noskaņojums

By Acuity

57%

43%

326 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

BioNTech SE ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. febr. 18:52 UTC

Galvenie tirgus virzītāji

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

2024. g. 15. nov. 10:28 UTC

Galvenie tirgus virzītāji

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

2024. g. 6. maijs 11:27 UTC

Peļņas

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

2024. g. 15. nov. 11:14 UTC

Tirgus saruna

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

2024. g. 15. nov. 10:34 UTC

Tirgus saruna

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

2024. g. 5. aug. 10:02 UTC

Peļņas

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

2024. g. 5. aug. 10:01 UTC

Peļņas

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

2024. g. 5. aug. 10:01 UTC

Peļņas

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

2024. g. 5. aug. 10:00 UTC

Peļņas

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

2024. g. 5. aug. 09:59 UTC

Peļņas

BioNTech 2Q Loss EUR807.8M >BNTX

2024. g. 5. aug. 09:59 UTC

Peļņas

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

2024. g. 5. aug. 09:59 UTC

Peļņas

BioNTech 2Q Rev EUR128.7M >BNTX

2024. g. 6. maijs 20:15 UTC

Peļņas

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

2024. g. 6. maijs 10:47 UTC

Peļņas

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

2024. g. 6. maijs 10:46 UTC

Peļņas

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

2024. g. 6. maijs 10:46 UTC

Peļņas

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

2024. g. 6. maijs 10:46 UTC

Peļņas

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

2024. g. 6. maijs 10:45 UTC

Peļņas

BioNTech 1Q Rev $187.6M >BNTX

2024. g. 6. maijs 10:45 UTC

Peļņas

BioNTech 1Q Loss $315.1M >BNTX

2024. g. 6. maijs 10:45 UTC

Peļņas

BioNTech 1Q Loss/Shr $1.31 >BNTX

Salīdzinājums

Cenas izmaiņa

BioNTech SE ADR Prognoze

Cenas mērķis

By TipRanks

54.57% augšup

Prognoze 12 mēnešiem

Vidējais 139.56 USD  54.57%

Augstākais 171 USD

Zemākais 110 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi BioNTech SE ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

14

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

87.605 / 95.61Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

326 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac